Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 13.7% – Here’s What Happened

Posted by Joseph Casey on Nov 8th, 2025

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares traded down 13.7% during mid-day trading on Thursday . The company traded as low as $64.6450 and last traded at $64.6450. 368 shares were traded during mid-day trading, a decline of 53% from the average session volume of 784 shares. The stock had previously closed at $74.8782.

Analyst Ratings Changes

ZLDPF has been the subject of several research analyst reports. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Thursday, July 24th. Five equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Strong Buy”.

Check Out Our Latest Analysis on Zealand Pharma A/S

Zealand Pharma A/S Stock Up 1.7%

The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08. The stock has a market cap of $4.77 billion, a P/E ratio of 4.72 and a beta of 0.71. The stock’s fifty day simple moving average is $72.64 and its 200-day simple moving average is $65.54.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). The business had revenue of $1.43 billion for the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. On average, research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.